This article was originally published in The Tan Sheet
Clinical trials comparing Zorex topical cold sore formula against two competitive products will be conducted by Boston University, Scottsdale, Ariz.-based firm announces. Clinicals are expected to last six months; if successful, results will be used to support advertising, marketing claims for Zorex, which contains monographed ingredient for pain, cold sore symptoms, as well as MTCH-24 compound. Meditech delaying regional launch of Zorex pending negotiations with five pharmaceutical companies (1"The Tan Sheet" April 2, In Brief)
You may also be interested in...
Firm plans to use proceeds from stock offering to regionally launch and market an OTC cold sore treatment by August, with a national rollout planned for January 2002. Zorex will contain a monographed ingredient for pain and symptoms of cold sores, as well as Scottsdale, Ariz.-based Meditech's MTCH-24 compound. Company also will use funds from sale of up to 73 mil. shares to complete clinical trials supporting an NDA for MTCH-24 as an OTC active for treatment of cold sores. Meditech is in talks with several pharma companies regarding licensing rights for Rx and OTC drugs containing MTCH-24. Results of company-funded study on Zorex's efficacy in treating herpes simplex will be presented at International Conference on Antiviral Research in Seattle April 10
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: